Rituximab biosimilar (Celltrion)

利妥昔单抗生物类似药（Celltrion）

Report date: 2023/05/06 09:02:22

Base Information

Drug NameRituximab biosimilar (Celltrion)
Drug Alias NameRituximab-abbs利妥昔单抗生物仿制药（Celltrion）RitemviaTruximaBlitzima +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaPemphigusLymphoproliferative Disorders +[23] 
Global Approved IndicationsMicroscopic PolyangiitisGranulomatosis with PolyangiitisArthritis, Rheumatoid +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/02/17
Country/TerritoryCanadaUnited StatesPuerto Rico +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesVcell Healthcare LtdNational Cancer InstituteCelltrion Healthcare Hungary Kft +[6] 
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaPemphigusAnemia +[19] 
Inactive IndicationsLymphoproliferative DisordersLymphoma, T-CellLymphoma, B-Cell, Marginal Zone +[4] 

Other Information

ATC CodeL01XC02
Related LinksN/A